viii. Discontinuation of an investigation 21 CFR 312.31(a)2

If the sponsor-investigator determines that an investigation drug presents an unreasonable and significant risk to subjects, she/he must discontinue the investigation within 5 working days after determining that the investigation should be discontinued.  A report of the discontinuation of the investigation should be submitted to the FDA within 5 working days of the discontinuance.